Telangiectases in Scleroderma: A Potential Clinical Marker of Pulmonary Arterial Hypertension
- 1 December 2009
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 37 (1), 98-104
- https://doi.org/10.3899/jrheum.090697
Abstract
Objective. Clinical markers are needed to identify scleroderma patients at risk for pulmonary arterial hypertension (PAH) since early therapy may improve survival. We investigated whether increased numbers of telangiectases in scleroderma associate with measures of pulmonary vascular disease. Methods. One hundred forty-seven consecutive adult patients with scleroderma were enrolled in this cross-sectional study and scored for the presence of matted telangiectases on 11 body areas. Per body area, telangiectases were scored as 0 if none were present, 1 if there were fewer than 10 telangiectases, and 2 if 10 or more telangiectases were counted. Linear regression analysis was performed to assess the association between right ventricular systolic pressure (RVSP) and telangiectasia score, adjusted for age, race, smoking status, scleroderma subtype, disease duration, and autoantibody status. Logistic regression analysis was performed with PAH by right-heart catheterization (RHC) as the dependent variable. Results. The mean telangiectasia score was 6.0 (SD 4.5, range 0–20). RVSP and telangiectasia score were positively correlated (r = 0.271, p = 0.001). The mean RVSP increased by 10.9 mm Hg for every 10-point increase in telangiectasia score (95% CI 3.6–18.3 mm Hg, p = 0.004), adjusted for potential confounders. The adjusted relative odds of PAH by RHC were 12.4 for patients with a 10-point increase in telangiectasia score (95% CI 1.78–85.9, p = 0.01). Conclusion. Increased numbers of telangiectases strongly associate with the presence of pulmonary vascular disease. Telangiectases may be a clinical marker of more widespread aberrant microvascular disease in scleroderma.Keywords
This publication has 19 references indexed in Scilit:
- Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglinRheumatology, 2008
- Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertensionRheumatology, 2006
- A Clue for Telangiectasis in Systemic Sclerosis: Elevated Serum Soluble Endoglin Levels in Patients with the Limited Cutaneous Form of the DiseaseDermatology, 2006
- Histopathological and ultrastructural features of dermal telangiectasias in systemic sclerosisPathology, 2005
- Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosisRheumatology, 2004
- Mutations in the activin receptor–like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2Nature Genetics, 1996
- Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1Nature Genetics, 1994
- Active proliferation of telangiectases in skin of patients with progressive systemic sclerosis (PSS)Archiv für dermatologische Forschung, 1986
- Ultrastructure and Three-Dimensional Reconstruction of Several Macular and Papular TelangiectasesJournal of Investigative Dermatology, 1983
- Preliminary criteria for the classification of systemic sclerosis (scleroderma)Arthritis & Rheumatism, 1980